Strategic US Partnership Capitalize on the US market collaboration with Provepharm to pursue co-manufacturing and distribution partnerships for injectables and generics, leveraging Sagent’s sterile fill‑finish capabilities and flexible packaging options such as eye drops, vials, syringes, and premix bags.

Ophthalmic Growth Focus With the Travoprost ophthalmic solution launch, target ophthalmology-focused opportunities by expanding the portfolio of sterile eye care products and offering end-to-end manufacturing and packaging services for ophthalmic generics.

Flexible Packaging Capacity Highlight flexible packaging capacity across multiple formats to accommodate partner pipelines and accelerate time to market for new products in diverse therapeutic areas.

Quality Assurance Enhancement Position as a quality partner by addressing past recall-related learnings and offering strengthened quality systems, sterile processing controls, and container-closure integrity improvements to mitigate risk for customers.

Acquisition Driven Expansion Leverage a track record of asset acquisitions and facility integration to position Sagent as a scalable manufacturing partner capable of rapid onboarding, regulatory alignment, and cross-border collaborations.